Tranexamic acid in burn surgery: A systematic review and meta-analysis.

Burn injury causes a coagulopathy that is poorly understood. After severe burns, significant fluid losses are managed by aggressive resuscitation that can lead to hemodilution. These injuries are managed by early excision and grafting, which can cause significant bleeding and further decrease blood cell concentration. Tranexamic acid (TXA) is an anti-fibrinolytic that has been shown to reduce surgical blood losses; however, its use in burn surgery is not well established. We performed a systematic review and meta-analysis to investigate the influence TXA may have on burn surgery outcomes. Eight papers were included, with outcomes considered in a random-effects model meta-analysis. Overall, when compared to the control group, TXA significantly reduced total volume blood loss (mean difference (MD) = −192.44; 95% confidence interval (CI) = −297.73 to − 87.14; P = 0.0003), the ratio of blood loss to burn injury total body surface area (TBSA) (MD = −7.31; 95% CI = −10.77 to −3.84; P 0.0001), blood loss per unit area treated (MD = −0.59; 95% CI = −0.97 to −0.20; P = 0.003), and the number of patients receiving a transfusion intraoperatively (risk difference (RD) = −0.16; 95% CI = −0.32 to − 0.01; P = 0.04). Additionally, there were no noticeable differences in venous thromboembolism (VTE) events (RD = 0.00; 95% CI = −0.03 to 0.03; P = 0.98) and mortality (RD = 0.00; 95% CI = −0.03 to 0.04; P = 0.86). In conclusion, TXA can potentially be a pharmacologic intervention that reduces blood losses and transfusions in burn surgery without increasing the risk of VTE events or mortality. • Reducing blood loss is a priority for burn surgery patients. • Tranexamic acid is an antifibrinolytic that reduces plasmin formation. • In burn surgery, tranexamic acid reduces blood loss. • Tranexamic acid does not increase the risks of complications in burn surgery. [ABSTRACT FROM AUTHOR]